Development of a Benzoxazine-derived Inhibitor Targeting Epithelial-to-Mesenchymal Transition in Lung Cancer. Phansom N, Ei ZZ, Innets B, Wattanathana W, et al. Anticancer Res 2025;45:2807-2815.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Phansom N, Ei ZZ, Innets B, Wattanathana W, et al. Development of a Benzoxazine-derived Inhibitor Targeting Epithelial-to-Mesenchymal Transition in Lung Cancer. Anticancer Res 2025;45:2807-2815.
PMID: 40578951